Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations.

ABSTRACT:

Background

Cancers that do not respond to immunotherapy typically harbor a non-T cell-inflamed tumor microenvironment (TME), characterized by the absence of type I/II interferon signaling and CD8+ T cell infiltration. We previously reported IDH1 somatic mutations were enriched in this phenotype across histologies. Mutant IDH1 (mIDH1) drives immune exclusion via metabolic reprogramming of the TME, and preclinical models show that IDH inhibition can restore anti-tumor immunity. We conducted a Phase II study assessing the preliminary activity of ivosidenib, an IDH1 inhibitor, plus nivolumab, an anti-PD1 antibody, in patients with mIDH1 advanced solid tumors (NCT04056910).

Methods

Patients with advanced or refractory mIDH1 solid tumors and no prior exposure to IDH1 inhibitor wer

SUBMITTER: Nguyen MK 

PROVIDER: S-EPMC12605714 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature